What We're Reading: Page 316
Industry reads hand-picked by our editors
Nov 29, 2016
Nov 28, 2016
-
EP Vantage
Why J&J shouldn’t buy Actelion
-
The Wall Street Journal
Drugmakers find competition doesn’t keep a lid on prices
-
NPR
Patients increasingly influence the direction of medical research
-
Reuters
French cancer specialist Innate Pharma can remain independent, for now: CEO
-
The Washington Post
New tricks in canine cancer research may improve treatments for humans, too
Nov 23, 2016
-
Bloomberg Gadfly
Biotech should cash in its Trump bump
-
The Wall Street Journal
Fentanyl billionaire comes under fire as death toll mounts from prescription opioids
-
MIT Technology Review
Do your family members have a right to your genetic code?
Nov 22, 2016
-
Boston Business Journal
Shire to buy Genzyme headquarters, plans to hire another 400
-
Bloomberg
At Valeant, all eyes on whether Philidor defendants acted alone
-
The New York Times
U.S. dementia rates are dropping even as population ages
-
CBS
Over 200 lawsuits claim Viagra led to increased risk of melanoma
Nov 21, 2016
-
Bloomberg Gadfly
Valeant's asset sale clock is ticking
-
Los Angeles Times
California Democratic Party leaders may be asked to fess up when paid to back ballot measures
-
The New York Times
The race for a Zika vaccine
-
Forbes
Biotech venture capital mythbusting redux
Nov 18, 2016
-
Reuters
One life, two donated organs and $5.7 million in bills – a tale of superbugs’ deadly costs
-
The Wall Street Journal
After rough patch, Gilead shouldn’t succumb to deal pressure
-
Bloomberg
NYPD union goes after drug prices amid DOJ pharma probe
-
Financial Times
High stakes: Eli Lilly's hunt for an Alzheimer's drug
Nov 17, 2016
-
The Boston Globe
FDA regulator defends decision to OK Sarepta drug
-
Chicago Tribune
Chicago to require pharmaceutical rep licenses despite industry objections
-
Slate
Homeopathic medicines will carry labels saying they’re unscientific
-
The Guardian
Long-lasting pill that releases malaria drug for two weeks a 'game-changer'
Previous
